Maternal RSV vaccination enhances antibody transfer to newborns, with optimal transfer efficiency observed when given at ...

Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...

Treatment with the anti-TIGIT antibody vibostolimab and Keytruda (pembrolizumab ... Common treatment-related side effects in ...

While countless long COVID sufferers put Pretorius’s theory to the test, her new focus is raising its awareness. Not only ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued ...

Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VCNX), a clinical-stage biotechnology ...